Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Australians pay some of the lowest medicine prices in the world for a reason: our Pharmaceutical Benefits Scheme. Here’s how ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by ...

HIGHLIGHTS •Aircore drilling to test priority targets expected to commence in late-March, weather dependent, at the Balla ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and ...

US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump ...

Novo Nordisk’s bid to provide a once-weekly basal ... but comes after insulin icodec has already been approved in the EU, Canada, Australia, Japan, and Switzerland under the Awiqli brand name ...

Maintaining a healthy diet rich in plant-based foods, with low to moderate intake of healthy animal-based foods and lower intake of ultra-processed ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

Let's see why these funds could be worth considering for your portfolio right now. The post These 2 ASX ETFs should ...

In the quest for health and wellness, Australians are constantly on the lookout for effective weight loss strategies. For ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study.